Table 2.
Efficacy analyses
| Population | Assessment | TSST | VQW-765 (n = 116) |
Placebo (n = 114) |
Difference (95% CI) | P-value | ||
|---|---|---|---|---|---|---|---|---|
| Mean | s.d. | Mean | s.d. | |||||
| ITT | SUDS | Pre-dose | 34.66 | 23.20 | 37.02 | 23.42 | ||
| Resting | 47.76 | 23.07 | 51.15 | 24.78 | −2.8 (−8.70, 3.14) | 0.1775 | ||
| Anticipation | 52.96 | 22.25 | 56.90 | 21.90 | −3.3 (−8.83, 2.23) | 0.1206 | ||
| Performancea | 58.6 | 23.96 | 62.26 | 22.40 | −3.2 (−9.13, 2.73) | 0.1443 | ||
| CGI-C | Post-TSSTa | 3.6 | 1.12 | 3.6 | 1.06 | −0 (−0.29, 0.23) | 0.4038 | |
| PGI-C | Post-TSSTa | 3.4 | 1.14 | 3.5 | 1.08 | −0 (−0.33, 0.25) | 0.3993 | |
SUDS, Subjective Units of Distress Scale; TSST, Trier Social Stress Test; CGI-C, Clinician Global Impression of Change; PGI-C, Patient Global Impression of Change; ITT, intention-to-treat; 50% quantile, middle 50% quantiles of VQW-765 plasma concentration; LSAS, Liebowitz Social Anxiety Scale. Difference (95% CI), least-square mean difference (95% CI).
a.
Primary efficacy analysis.
b.
Secondary efficacy analysis.